Crucell swings to 3rd-qtr profit of $15.7M
Dutch biotechnology firm Crucell NV achieved its first ever quarterly profit, with third-quarter 2008 net income of 12.3 million euros ($15.7 million), versus a net loss of 4.5 million euros in the same period last year.
The firm earned 0.19 euros per share vs a deficit of 0.07 per share, as combined revenue and operating income jumped 31% to 82.1 million euros (38% in constant currencies), thanks to strong sales of pediatric vaccines as well as higher license income, driven by milestone payments for the results of a Phase II study of a rabies monoclonal antibody combination and for Sanofi Pasteur's seasonal influenza vaccine FluCell.
Product sales for the third quarter amounted to 65.6 million euros and represent sales of pediatric vaccines (44%), travel and endemic vaccines (16%), respiratory vaccines (30%) and other agents (10%).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze